From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and ...
Institute of Neuroscience, Howard Hughes Medical Institute, University of Oregon, Eugene, United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback